Please login to the form below

Not currently logged in
Email:
Password:

orphan diseases

This page shows the latest orphan diseases news and features for those working in and with pharma, biotech and healthcare.

Raising awareness and encouraging support on Rare Disease Day 2020

Raising awareness and encouraging support on Rare Disease Day 2020

These include:. New requests for applications for the Orphan Products Grants programme, which supports natural history studies and clinical trials for rare diseases. ... Raising awareness is central to our mission to improve outcomes for people affected

Latest news

More from news
Approximately 3 fully matching, plus 120 partially matching documents found.

Latest Intelligence

  • Biopharma and orphan drugs Biopharma and orphan drugs

    Rare disease regulations. Twenty one of the 48 novel drugs approved in the US were for rare or orphan diseases – those that affect fewer than 200, 000 citizens. ... Clinical complications. Given the rarity of orphan diseases, one of the greatest

  • Industry needs an aligned position on the future of the EU OMP Regulation Industry needs an aligned position on the future of the EU OMP Regulation

    The Pharmaceutical Strategy is likely to include innovation-boosting measures and plans to revise the EU Regulation on Orphan Medicinal Products (OMP Regulation). ... of orphan diseases).

  • BRIC markets BRIC markets

    drug list, list of 24 orphan diseases, list of seven nosologies, and other programmes, depending on region.

  • The changing nature of approvals – what does the future hold? The changing nature of approvals – what does the future hold?

    Small and mid-sized companies can concentrate on specific development areas, innovative products and diseases with smaller target populations. ... However, rare diseases and orphan drugs are also emerging as important focal areas.

  • The trials and tribulations of rare opportunities The trials and tribulations of rare opportunities

    Pharmaceutical industry interest in developing treatments for rare diseases is increasing, for understandable reasons. ... Humira, the world’s best-selling drug, has multiple orphan designations. Likewise Soliris (eculizomab) – which generated

More from intelligence
Approximately 0 fully matching, plus 35 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 18 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Empowering Strategic Performance Ltd

OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...

Latest intelligence

Patients are ready to embrace decentralised clinical trials, are you?
Traditional clinical trial designs simply can’t withstand the impact of COVID-19. While before the pandemic, some in clinical research were beginning to adopt virtual components, the move towards designing hybrid...
Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....

Infographics